Multivariable logistic regression analyses accounted for demographic, disease and insurance characteristics. Only 10.8% of those <40 years old had never received disease-modifying medications, compared with 41.1% of persons aged 60-64. Among the uninsured, 36.8% reported having never taken these ...
Newer agents have since become available and have significantly changed the dynamics of MS treatment. These include fingolimod, dimethyl fumarate and teriflunomide, which are oral agents. Other second-line and third-line Food and Drug Administration (FDA) approved medications include natalizumab and ...
MS is characterized by formation of white matter lesions in the CNS as a result of inflammation, demyelination, and axonal loss. Treatment has been a focus of neurological research for over 60鈥厃ears. A number of disease-modifying therapies (DMTs) have become available making MS ...
While western medicine has found no cure for MS, several drug therapies are employed varying from disease modifying drugs to therapies for symptomatic amelioration. There are several types of diagnosable MS including the following, though several more may be possible. Each type may be mild, ...
PD has serious issues for both patients and clinicians, because this disorder is typically difficult to treat with traditional pharmacological approaches once develop due to the complexicity of the nervous system and physical barriers that limit distribution of medications into the central nervous system...
Disease Modifying Therapies (DMTs) The conventional approach to treatingMSincludes the use of medications to controldisease activityand some symptoms and rehabilitation interventions to alleviate symptoms resulting from damage to the CNS. Medications that help decreaseMS diseaseactivity are referred to as ...
Ward N. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980 -1995: results from the National Ambulatory Medical ... MM Ward - 《Journal of Rheumatology》 被引量: 376发表: 1999年 Trends in the Use of Disease Modifying Antirheumatic Medications among Patie...
Cases of PML have occurred in patients with MS receiving fingolimod in the postmarketing setting who had not been previously treated with natalizumab nor who were taking immunosuppressive or immunomodulatory medications concomitantly [13]. In addition, affected patients had no other ongoing identified sys...
Background: Most disease-modifying therapies (DMTs) for multiple sclerosis (MS) are self-injectable medications that must be taken on an ongoing basis ... V.,Devonshire,Y.,... - 《European Journal of Neurology》 被引量: 285发表: 2010年 Update on monitoring and adverse effects of approv...
People with multiple sclerosis (MS) face challenges adhering to disease-modifying drug (DMD) treatment. Poor adherence to treatment reduces its clinical ef